Thank you for subscribing!

Psychedelic Wellness Treatment w/ Global Presence

Why Silo Wellness is the Best Hedge in this Red-Hot Market

  • dCurrently Undervalued – The two biggest competitors both have a market cap of a little over $1B, and most of Silo’s other competition boast caps 10x or more their own. The opportunity to invest before Silo’s cap catches up could be closing.
  • Brand PowerAfter signing a multi-year licensing agreement with the family of legendary musician Bob Marley for the exclusive worldwide rights to produce, market, and sell products under the famous musician’s name, Silo Wellness now has the name of one of the most famous musicians of all time.
  • Growing MarketThe future of psilocybin is promising, but in the meantime, Silo is advancing its interest in the functional space, currently worth $34B (and growing at a CAGR of 8%).
  • Combining Psychedelics and PharmaceuticalsThe company recently announced its intent to acquire Dyscovry Science, a Toronto-based biotechnology company that focuses on biosynthetic manufacturing of psilocybin and its derivatives. This acquisition, if finalized, will give the Silo Wellness a huge advantage no matter which direction the psychedelic medicine market goes in the years to come


Silo Wellness (CSE: SILO | OTC: SILFD | FRA: 3K70) is, quite simply, the next big thing in the psychedelic space. In fact, with the Marly One brand partnership, and a growing wave of attention from the mainstream press, one could argue it might already be the biggest thing you haven’t heard of. Yet. 

Silo is a global psychedelics and wellness company, delivering psychedelic healing through functional mushrooms (no-trip) and healing retreats (yes-trip). Oh, and did we mention that it is already generating revenue? Because it is. Silo provides services in two countries, has global product distribution, and its partnership with the Marley One brand portfolio all generate revenue NOW, while also boosting Silo’s global footprint. 

We’ll get to the specifics momentarily, but the TLDR is this: while most psychedelic companies you hear about are waiting on government funding or stuck behind red tape, Silo is already generating revenue and gobbling up market share.

All this while a wave of public awareness is coming to the legal psychedelics space. A quick sweep of the internet provides a deep dive into the business and culture of psychedelics, with Silo being prominently featured by mainstream publications like Outside Magazine, Forbes, Buzzfeed News, and more. The Silo name is already climbing the public awareness list in a blossoming market. It’s in the title for a reason: this company is your best hedge against the psychedelic companies that rely on a novel-compound to be approved for pharmaceutical use.


Major Considerations for Silo

Revenue Generating

Many psychedelic companies are involved in multi-year processes that result in a massive cash burn, with any revenue potential years down the road. Silo is different. Because of their approach to wellness, they have already been generating revenue. This proof of monetization via product sales, wellness retreats, and partnerships gives Silo an edge in the marketplace that can’t be ignored.

Brand Recognition

Without a key differentiator, most products get lost in the shuffle. Again, Silo has proven to be ahead of the competition. Its partnership with the Marley One brand, and relationship with the Marley family, makes Silo’s products the most recognizable in the game. Bob Marley is undoubtedly one of the biggest names in music history, and his legacy remains strong, with over 1B song downloads in the U.S. alone, while the Marley brand boasts a 70M strong social media presence. When Silo announced the partnership with Marley One, it generated over 22M earned views, and its footprint only continues to grow. Having a powerful, recognizable brand is one of the best ways to ensure long-term success, and Silo has found that in Marley One.


Silo is definitely not the only company in the psychedelic wellness space. And while it isn’t necessarily a crowded room, it’s a room filled with big players. Mind Med and Field Trip both have a market cap of a little over $1B, and most of Silo’s competitors boast caps 10x or more their own (roughly $5M at the time of this writing). In some ways, this is good news for potential investors, as this is your chance to get on the train before it leaves the station.

Mental and physical health

With its recently announced acquisition of Dyscovry Science, Silo’s investors will gain access to a government recognized pharmaceutical company using psilocybin and its derivatives to treat a physical condition (Irritable Bowel Syndrome) in addition to the existing mental health side of the business.

A Unique Approach

Silo has, smartly, diversified their approach to providing healing. It currently offers legal psychedelic retreats (ketamine in Oregon, and Psilocybin and 5-Meo-DMT in Jamaica), functional (read; no-trip) mushrooms via the Marley One partnership,their own line of mushrooms, a patent-pending psilocybin nasal spray, and mushroom cultivation. The big takeaway here is that Silo is not dependent on approval for the use of a novel molecule; it is scaling as legislation changes, and it is focused on the direct application of what is currently legal. This approach will give Silo the upper hand as they will not be wholly reliant on one area of revenue to succeed.

The Future of Wellness

Among 35-55 year olds, especially in tech/start-up type businesses, wellness retreats are extremely popular. Gone are the days of 5 day “empowerment” seminars. Today’s professionals want a luxury trip somewhere beautiful and safe to work on healing their inner-psyche. Silo is offering just that, and its earned media placements in publications like Bloomberg and the Washington Post have led to a pre-qualified pipeline with a mile-long waitlist. Each retreat Silo has run is fully booked and it is working to schedule more. This revenue stream is the future of both tourism and wellness.

Socially Conscious 

An area of growing importance in the investment landscape is social consciousness. Is the company aware of the cultural importance of what many people view as sacred? In the case of Silo, yes. It is making efforts to integrate indigenous practices in its wellness retreats, emphasize the importance of giving back to the community, and giving credit to the cultures that originated these alternate wellness pursuits. From a purely optics standpoint, this gives Silo enhanced respectability, and plays well with its target audience.

Silo’s partnership with the Marley One brand provides great value to the brand. Two moves on the distribution side this year should add even more value that is hard to come by with industries moving into the realm of widespread legalization: consumer accessibility.

In August, Silo and One Light Enterprises announced a $3 million distribution agreement that made Marley One’s full line of mushroom products available to the American public. Two months later, Silo expanded its reach when listed the company’s portfolio of functional mushroom products on their retail platform. This alone made products available to more than 197 million people who reportedly visit the online marketplace each month — more than the entire population of Russia.

“From inception, our primary focus has been to broaden acceptance and support for the normalization of mushrooms and psychedelics and to make both available today, wherever possible, to help reduce trauma, enhance performance and create revenue in this burgeoning industry now. Our listing on Amazon, one of the largest e-commerce platforms in the world, takes us one step closer to that goal,” said CEO Douglas K. Gordon

Delivering Psychedelic Healing, NOW

It’s hard to pretend we’re not excited about Silo’s potential. So we won’t. We’re really excited. Silo is doing all the things we like to see in emerging companies: establish a stream of revenue, build a recognizable brand, create strong partnerships, have a clear vision, and do something a little different. When you take into account the projected growth for psychedelics, in conjunction with cultural trends, we think it’s possible Silo could go vertical any second.

Market Potential

Real quick, let’s talk about just how rich the soil is in the markets Silo is playing in. The global anti-depressant drug market was valued at $13.8B in 2016, and is expected to grow to $16B by 2023. Meanwhile, a 2017 poll showed 59% of U.S. consumers would consider using psychedelics as a treatment if diagnosed with a mental health condition for which it had been proven effective. That means by 2030, Silo is playing with a TAM worth roughly $8B in the antidepressant drug market alone. According to Mordor Intelligence, the global functional mushroom market was worth $25.4B in 2020 and is estimated to register a CAGR of 8.44% through 2026. All this while the market research predicts increased applicability for functional mushrooms beyond healthcare and pharma products over the long term.

Silo’s involvement in functional mushrooms, and the surrounding applications, represents over $400B of commerce. If it can capture even a small slice of these markets, it will become the biggest name in psychedelic wellness practically overnight. With the power of the Marley name behind it, Silo is positioned to grow quickly into a powerhouse provider within these markets.

Marley’s Legacy

Silo has been busy working on distribution deals for its range of functional mushroom products under the Marley One brand. After signing a multi-year licensing agreement with the family of legendary musician Bob Marley for the exclusive worldwide rights to produce, market, and sell products under the famous musician’s name, Silo Wellness dove right in.

Celebrity endorsements are always helpful. But there is something especially powerful about the association Silo now has with Bob Marley. Few performers have ever reached the kind of popularity that Bob Marley did, and even fewer have maintained (and even grown) their reach posthumously. Thanks to his family, Bob Marley’s legacy has remained strong.


“Our family is happy to collaborate with Silo Wellness to create the first ever global mushroom brand,” commented family matriarch Rita Marley in a recent press release. “When Bob and I were young we followed a strict, natural diet and we would include medicinal mushrooms. Mushrooms fit with our vision of a world transformed for good through natural products.”


“These are transformative times in which we are living. Our family seeks to use our platform to help facilitate positive change. Mushrooms have been used for centuries, and we believe they offer a natural pathway for healing and positivity,” stated Cedella Marley, daughter of Rita and Bob Marley.

The initial launch of Marley One featured a range of functional mushroom tinctures with unique blends designed to offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement. Silo is working to bring wellness to as many people as possible, and the Marley One partnership is already proving to be a move in the right direction.

In mid-August, Silo announced a $3 million national distribution agreement with Texas-based distribution and advertising company One Light Enterprises LLC. for its portfolio of Marley One branded mushroom products across 47 U.S. states. This announcement came on the heels of a previous announcement that U.K. brand distributor LocoSoco Group Plc. had committed to a $1.4M minimum order of Marley one products. Not bad, considering that the Marley One brand only debuted earlier this year.

Since then, Silo has also signed a distribution deal with the UK-based company, Flawless CBD Distribution, to further their mission to remove the stigma against the medical use of hallucinogens.

The partnership with Flawless CBD Distribution also happens to coincide with the kickoff of the ​​Bob Marley ‘One Love’ Experience at Saatchi Gallery, in Chelsea. The exhibition will showcase never-before-seen Marley photos and memorabilia while discussing the artist’s life journey, and will reside in Chelsea for ten weeks before embarking on a global, multi-city tour.

All of this recent company news culminates as Silo Wellness begins a partnership with UVertz, a revolutionary advertising platform. This partnership will result in Marley One ads being displayed in 50 cars in NYC whose drivers utilize gig economy apps such as Uber and Lyft and is designed to increase brand familiarity, recognition, and confidence.

Psychedelics meet Pharmaceuticals

As we mentioned earlier, the company has executed a nonbinding letter of intent to acquire Dyscovry Science, a Toronto-based biotechnology company that focuses on biosynthetic manufacturing of psilocybin and its derivatives.

This is huge news for Silo Wellness, and the implications for investors could be game changing.

Unlike most of its peers in the psychedelics space, which focus on mental health issues, Dyscovry is targeting a physiological condition: irritable bowel syndrome. In addition, the company has research collaborations with Canadian federal government research laboratories intended to further development of a biotechnological process for the production of psilocybin and its potentially novel molecule derivatives.

This acquisition gives psilocybin and Silo Wellness more credibility, bringing natural healing solidly into the realm of exact science.

Silo President and Founder Mike Arnold explained, “We have watched the psychedelic market get pummeled as many have been chasing the ‘me too’ pharma deals, while we stayed focused on preparing for Oregon adult-use with a successful Jamaican retreat model while, in the background, working on this unique opportunity. For the first time under one roof, a publicly-traded company will provide psychedelic healing right now through Jamaican psychedelic wellness retreats while at the same time innovating the ‘what’s next’ for psychedelic pharmaceutical healing.”

Dyscovry CEO  Gerard Lee added “By Dyscovry’s research team focusing on investigating a quantifiable anti-inflammatory effect of psychedelics, Dyscovry has embarked on the rigorous scientific investigation of enhanced biosynthesis of psilocybin, as an alternative therapeutic option to both naturally-occurring and chemically-synthesized psilocybin. The downstream goal is to bring regenerative medicine approaches to the treatment of IBS”

This upcoming acquisition is major news for investors, as Arnold explained.

“We believe we will be the only company with deep roots in Oregon that is actively providing psilocybin to paying guests in the western hemisphere (Jamaica) while at the same time working a pharmaceutical opportunity (Dyscovry). In other words, if the future of psychedelic medicine is a state-by-state legalization akin to cannabis, we intend to have you covered. If the future is pharma, we have an asset for you as well. If these parallel avenues go forward simultaneously with a thriving adult use market in addition to pharma, then freedom wins, and the world is better for it. We intend to be a leader in the space and hope to bring inexpensive psychedelic healing to as many people in need as possible.”


Mushrooms are Growing (in Popularity) 

With the steady legalization of marijuana, the attitudes toward other substances have begun to shift rapidly. Legal ketamine clinics are popping up all over the U.S. to treat depression, and it’s only a matter of time before psilocybin is legal for medical use as well. An article by the Observer indicates that legal psychedelics as a whole are forecast to be a $6.7B market by 2027. 

As the perception of these substances continues to change, Silo is perfectly positioned to dominate the space via stellar brand recognition. And they aren’t limited to psychedelics. The majority of Silo’s current product efforts are focused on the functional mushroom space. Mushrooms like Lion’s Mane, Chaga, Rooster Tail, and more have been proven to improve cognition, mood, and increase overall well-being. The future of psilocybin is promising, but in the meantime, Silo is advancing its interest in the functional space, currently worth $34B (and growing at a CAGR of 8%).


Investors are catching on to the fact that psychedelics are going to be big. And Silo is set to deliver. In addition to a new media campaign in New York City, featuring targeted on-the-go ads in the windows of rideshare cars, it recently announced Marley One’s sponsorship of ‘For The Love of Hip Hop’ – a virtual concert series exclusive to the metaverse – with the first event of the series being held on February 11. 

This cutting-edge digital event marks a forward-thinking brand threading the needle between innovation and maintaining a connection to its core consumers. It’s this kind of strategy that has us excited about the future of Silo. 

“We’re thrilled to celebrate Marley One’s official arrival to the metaverse as a leading sponsor of ‘For The Love of Hip Hop’, a completely virtual concert series featuring a star-studded lineup of artists,” said Douglas K. Gordon, CEO of Silo Wellness. “As innovative first-movers in the psychedelics and functional mushroom categories, we’re always proud to support future-forward ventures – and the Marley One brand is forever married to music. From psychedelics to virtual reality, Marley One remains at the forefront of cultural moments and community events.”

‘For The Love of Hip Hop’ will bring all the functionality of the metaverse, offering an interactive virtual experience packed with wonderful visuals and sounds for all who attend. This unprecedented way to experience music will bring people together like never before, giving them front-row access to legendary hip hop artists.

The New Age of Empowerment  – Move Over Tony Robbins

Mushrooms, microdosing, and other forms of alternative wellness are exploding in popularity among the 35-55 age groups, especially for those in startup/tech related professions. We all remember the “Unleash Power Within” Tony Robbins seminars. Walk across some hot coals and scream really loud, and maybe you’ll double your sales (or whatever). Silo is offering the newer, better, version of those.

Silo is engaged in an interesting branch of treatment, labeled “psychedelic retreats”. It’s exactly what it sounds like. People go to a location (Jamaica for mushrooms, Oregon for Ketamine), where they are guided by trained professionals through a healing psychedelic experience. 

“We are prioritizing the expansion of our wellness retreat offerings to meet rising consumer demand for these transformative psychedelic experiences,” said Chief Executive Officer Douglas K. Gordon in a press release. “Setting and mindset have a profound influence on an individual’s experience, and our Jamaican retreats offer idyllic, natural backdrops for engaging in psilocybin-assisted exploration, introspection and self-actualization.”

A study published in November 2020 by Research and Markets valued the overall wellness tourism industry at $735.8B; by 2027, the agency projected it would be worth $1.2T. Silo’s ventures into this space have been successful so far, with more wellness retreats planned as legalization spreads.

So what does a psychedelic retreat look like? The Renew Your Purpose retreat in early 2022 was a five day, four night psilocybin-assisted seminar, of sorts, in which guests participated in activities led by author Jessica Huie. Huie’s book Purpose served as a bit of a syllabus for the activities, helping participants focus on self-reflection and purpose.

“I felt like a neural pathway in my brain had opened up. There was a release,” said Whitney Leming-Salisbury, a Renew Your Purpose retreat participant from the United States. “The combination of yoga, ceremonies, the workshops and one on one sessions with the guides, really solidified my integration with the medicine.”

“This is why we do what we do,” said CEO Douglas K. Gordon, “to safely introduce individuals to psychedelics in a legal place in the western hemisphere.”

Bringing Innovation to the Product Sector

Providing an atmosphere and experience for psilocybin treatments is one thing, but Silo is also actively working at delivery methods through product innovation.

In April 2021, the company signed a LOI for a multi-year patent licensing agreement to exclusively manufacture, promote, advertise, distribute and sell Jungle Med’s patent pending, metered-dosing psilocybin nasal spray in Colombia and Brazil. The IP has great potential in the psilocybin market, as it delivers treatment in an alternative and effective way. While mushrooms are typically digested like any other food, the metered-dosing nasal spray provides an accurate dosage — something eating can’t accomplish — and creates a quicker uptake. This faster uptake speed is critical to preventing accidental stacking of doses, similar to the problem of cannabis edibles, and it brings some much-needed innovation to how people ingest psilocybin.

The Press Loves Silo (and the Psychedelic Movement)

So, you’ve read some numbers and see that all signs point to growth in the psychedelics space. But why Silo

Well, any growing company can make smart investments, secure strong partnerships, and make all the right marketing moves. But you can’t just buy the type of good press Silo is receiving.

Mainstream media outlets are highlighting the psychedelics cultural movement with in-depth storytelling — a useful tool for psychedelics to earn public favor in the health and wellness field. But beyond driving interest in the culture at large, names like Bloomberg, The Washington Post, Outside Magazine, Buzzfeed News, and others are turning specifically to Silo for their reporting. The brand is being placed in the forefront on this ride to public awareness. 

Buzzfeed’s John Semley penned a lengthy narrative feature detailing his experience with 5-MeO-DMT during a wellness retreat this year. In it, Semley joined one of Silo’s retreats in Montego Bay and gave a detailed  and highly informative account of his experience with “The God Molecule.”

David Kushner of Outside Magazine examined Silo’s approach to treating mental illness and its work with ketamine and psilocybin, declaring that the “future of nature therapy is psychedelic.”

Could they really be a radical new way to solve mental health problems?” Kushner asks. “A lot of serious people, ­including activists and research scientists, believe there’s potential to develop important techniques that really contribute to healing.” 

Kushner points out that Silo received more than 100 inquiries for just five spots in the retreat he observed, suggesting there is already a flood of demand for what Silo offers.

Is an Innovative New Sector of the Festival Culture Boom Brewing? 

Silo announced in early 2022 that its popular subsidiary Marley One would be a headline sponsor of ‘For Love and Hip Hop,’ an innovative concert held in the metaverse — yes, in the metaverse. The company is certainly getting creative with their marketing, and gaining brand recognition while piggybacking on the popularity of another cultural trend, festivals, shows some ingenuity. The festivals and events industry will be worth an estimated $2.19 trillion by 2028, riding an impressive 13.48% CAGR.

Silo’s magic is in the experiences it’s creating for customers. An innovative concert in the multiverse here with the Marley One banner headlining it all. Personal, intimate psychedelic wellness retreats plugging into a burgeoning new vacation culture there. Looking at Silo as more than a company moving products off of shelves reveals multiple revenue streams into the future.

Make Room for the Shroom Boom

Silo Wellness is, quite simply, in the sweet spot for massive growth. It is revenue generating, has the power of multiple trends behind it, boasts a diverse portfolio of products and offerings (almost all of them already providing revenue), and arguably has the largest social footprint and brand recognition of anyone in the space. Moreover, Silo is vastly undervalued when compared to the competition, and the pending acquisition of Dyscovry Science has the potential to bring psychedelic wellness squarely into the realm of exact science by treating physical conditions as well as mental.The rapid expansion of the Marley One brand will be driving growth in the short term, with the U.K. and U.S. distribution deals already in place. Silo will also be releasing their own branded product line in the same vein, while endeavoring to open brick and mortar mushroom shops as legislation allows. Its business is a big one, with hands in multiple avenues of healing.

The bottom line is, especially with the acquisition of Dyscovry, we think that  Silo Wellness won’t be undervalued much longer.


Recent News and Press Releases

Press Releases


Chief Executive Officer
Douglas K. Gordon

Chief Financial Officer
Winfield Ding

Legal Counsel and Corporate Secretary
Kenny Choi 




Who are we and what do we do? We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”). How is the Information published? We publish the Information on our Website, in newsletters, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer or third party paying us. Our publication of the Information is known as a “Campaign”. Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. How is a potential investor impacted if he receives the Information later than other investors? Typically, the trading volume and price of a Profiled Issuer’s securities increases after the Information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer increased trading losses if he purchases the securities of a Profiled Issuer. What will happen to the shares that we hold during the Campaign? We will sell the shares we hold while we tell investors to purchase during the Campaign. What will happen when the Campaign ends? Most, if not all, of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profiled Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment. Why do we publish only favorable Information? We only publish favorable information because we are compensated to publish only favorable information. Why don’t we publish negative Information? We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information. Is the Information complete, accurate, truthful or reliable? No. The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. What we do not do? We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities. Where does the Information come from? The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources. If we say we make “stock picks,” are those picks our own? No, they are not. We are compensated to advertise the securities we are told to advertise. What will happen if an investor relies on the Information? If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision. Who pays us to publish the Information? The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities. The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”. What warranties do we make about the Information? None. We make no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation. What we are not. We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
  • An independent adviser or consultant;
  • A fortune teller;
  • An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
  • A broker-dealer or an individual acting in the capacity of a registered representative or broker;
  • A stock picker;
  • A securities trading expert;
  • A securities researcher or analyst;
  • A financial planner or one who engages in financial planning;
  • A provider of stock recommendations;
  • A provider of advice about buy, sell or hold recommendations as to specific securities; or
  • An agent offering or securities for sale or soliciting their purchase.
Are risks in this disclaimer the only risks investors should be aware of? No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer. What conflicts of interest do we have in publishing the Information? We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. What will happen to the shares that we hold during the Campaign? We will sell the shares we hold while we tell investors to purchase. Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
  • We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
  • We do not publish any negative information whatsoever about the Profiled Issuers;
  • We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
  • A short time after we acquire a Profiled Issuer’s securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
  • Parties holding a Profiled Issuer’s securities, including those who engage our services and/or compensate us, will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
Who is responsible if an investor relies on the Information? The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions or errors in the Information, and we are not responsible for actions taken by any person who relies upon the Information. What do we urge potential investors to do? We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, or other available public sources. Why is this Disclaimer being provided? We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell our own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns. What are other risks that investors should be aware of? Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
  • We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
  • If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
  • The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
  • The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
  • You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
  • We or other stock promoters may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
  • We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
  • When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
  • The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
  • If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement Action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
  • We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and fail to disclose their compensation to you.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at, or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at and You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at What we were paid to advertise the Profiled Issuers. The details of our compensation and the period of the Campaign is set forth below.
  • Name of Issuer & Ticker Symbol - Silo Wellness (SILFD)
  • Amount & Form of Compensation - $500,000.00 in Restricted Common Stock
  • Who Paid for the Campaign & Position with Company if any - Silo Wellness (SILFD)
  • Period of Campaign - 09/15/2021 - 09/15/2022
What securities of the Profiled Issuers do we hold? The positions we hold of the Profiled Issuer are set forth below. We plan to sell these securities during the Campaign.
  • Name of Issuer & Ticker Symbol - Silo Wellness (SILFD)
  • Number of Shares We or our Affiliates Hold - 5,000,000,000
  • Price We Paid Per Share - $0
  • Date Issued - 08/17/2021

Related Post

Register to Download the Presentation

Go to website
Go to top